Dostarlimab
About
Therapy type: Immunotherapy
Therapy strategy: PD-1/PD-L1 inhibition
Mappings
NCI Thesaurus: Dostarlimab (ncit:C126799)
RxNorm: dostarlimab (rxcui:2539967, omop:1536789)
SNOMED: Dostarlimab (sctid:1156877005, omop:608113)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | dMMR | Endometrial Carcinoma | Carboplatin, Dostarlimab, Paclitaxel | |
| FDA (1) | MSI-H | Endometrial Carcinoma | Carboplatin, Dostarlimab, Paclitaxel | |
| FDA (1) HC (1) | dMMR | Endometrial Carcinoma | Dostarlimab | |
| FDA (1) | dMMR | Any solid tumor | Dostarlimab | |
| HC (1) | MSI-H | Endometrial Carcinoma | Dostarlimab |